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There are over 14,000 newly diagnosed rectal cancers per year in the United Kingdom of which between 50 and 64 percent are
locally advanced (T3/T4) at presentation. Pelvic exenterative surgery was ﬁrst described by Brunschwig in 1948 for advanced
cervical cancer, but early series reported high morbidity and mortality. This approach was later applied to advanced primary rectal
carcinomas with contemporary series reporting 5-year survival rates between 32 and 66 percent and to recurrent rectal carcinoma
with survival rates of 22–42%. The Swansea Pelvic Oncology Group was established in 1999 and is involved in the assessment
and management of advanced pelvic malignancies referred both regionally and UK wide. This paper will set out the selection,
assessment, preparation, surgery, and outcomes from pelvic exenterative surgery for locally advanced primary rectal carcinomas.
1.Introduction
There are over 14,000 newly diagnosed rectal cancers per
year in the United Kingdom [1]o fw h i c hb e t w e e n5 0a n d6 4
percent are locally advanced (T3/T4) at presentation [2, 3].
Preoperative imaging now accurately identiﬁes involvement
of adjacent pelvic organs (T4 disease) which precludes con-
ventionalresectionstrategies.Localrecurrenceafterprevious
rectal cancer surgery, with an incidence of 5–15 percent,
shares a common approach to the evaluation and surgical
approach to primary T4 rectal cancer.
The state-of-the-art approach to rectal cancer includes
high quality audited total mesorectal excision (TME) sur-
gery, cylindrical abdominoperineal excision, and extended
resections,whicharebeyondnormalanatomicalboundaries.
The primary aim of surgery is to obtain clear resection
margins to avoid future local recurrence. Pelvic exenterative
surgery was ﬁrst described by Brunschwig in 1948 [4]f o r
advanced cervical cancer, but early series reported high
morbidity and mortality. This approach was later applied
to advanced primary rectal carcinomas with contemporary
series reporting 5-year survival rates between 32 and 66
percent[5,6]andtorecurrentrectalcarcinomawithsurvival
rates of 22–42% [7].
2. Aim
The aim of this paper is to set out the criteria for selection
of patients suitable for radical treatment of primary locally
advanced rectal carcinoma to oﬀer the possibility of cure.
It will also set out to establish the need for this surgery
to be undertaken in high-volume centres with a specialist
interest in the management of advanced pelvic malignancy
(including urogenital malignancies), the need for a specialist
pelvic oncology MDT, and the need for a team with an
expressed interest in these challenging cases.
3. Approach
The Calman-Hine Framework [8] has recommended that
cancer services be delivered via a site-speciﬁc multidisci-
plinary team (MDT). Others have suggested however that,
in the case of advanced pelvic malignancy, a dedicated
multispeciality team would be more appropriate for the2 International Journal of Surgical Oncology
assessment and management of these diﬃcult cases [9,
10]. To this end the Swansea Pelvic Oncology Group was
established in 1999 and is involved in the assessment and
management of advanced pelvic malignancies referred both
regionally and UK wide.
With small numbers of patients suitable for exenterative
surgery, the role of a multispecialist team covering a large
geographical area cannot be underestimated. This approach
leads to the development of substantial experience and
delivers high-volume and high-quality surgery [11, 12]. The
group has operated on over 350 pelvic oncology patients
since 1999, averaging 32 cases per year. The involved
specialities in this group include colorectal, gynae-oncology,
urological, plastic reconstructive, orthopaedic, and neuro-
surgical surgical teams together with radiology, pathology,
and oncology support. The team should meet on a weekly
basis in an MDT forum to discuss optimal treatment of these
highly individualised patients.
4. Extentand Justiﬁcation for
Exenterative Surgery
It is estimated that approximately 10% of all colorectal car-
cinomas are found to be locally advanced and invading adja-
centstructuresbutwithoutmetastaticdiseaseatpresentation
[13]. It has long been known that there are variants of col-
orectal cancer that favour local invasion without metastatic
potential making this group particularly suited to local
radical surgery which translates into long-term survival [14].
Although many tumours exhibit adhesions to adjacent
structures, it would not be true to say that all of these are
malignant invasion. The incidence of these adhesions being
malignantvariesindiﬀerentseriesbetween40and84%[13].
However, in these cases it is certainly true that less than
radical en bloc resection increases the local recurrence rate
and compromises patient survival [15–17]. In one study 5-
year survival in en bloc resection was in the order of 61%,
but this fell to 23% when tumours were separated from the
organs to which they were adherent, similarly with local
recurrence, en bloc resection had a local recurrence rate of
36% versus 77% if tumours were separated [15].
Furthermore, the evidence suggests that before setting
out on pelvic exenterative surgery the intent at surgery must
be to undertake a curative resection with histologically clear
resection margins. This needs to be predicted preoperatively
in order to keep those patients having a trial dissection or
“open and close” surgery to a minimum. Resection planes
can be accurately predicted with modern high-resolution
imaging. Results from the Swansea Pelvic Oncology Group
[11] demonstrate that resections for advanced pelvic mali-
gnancy with clear margins demonstrate a 5-year survival
of 53%. There was no survival advantage in patients with
positive margins, palliative surgery, and no surgery with
median survivals of 12 months, 9 months, and 13 months,
respectively. Negative resection margins and node-negative
status were associated with a 53% ﬁve-year survival,
reﬂecting acceptable long-term survival in a group whose
only other option is palliation.
5. Assessment andImaging
Locally advanced rectal cancer may involve such adjacent
organs as the bladder, prostate, seminal vesicles, urethra,
ureter, uterus and adnexa and sacrum. Direct invasion of
these structures may be amenable to radical exenterative
surgery and potential cure in appropriately selected patients.
Each case of locally advanced rectal carcinoma referred
for consideration for radical surgical treatment should be
assessed on an individual basis and independently by the
multispecialtyteam.Theprimaryfunctionofthisassessment
is to review the clinical, pathological and radiological
ﬁndings of the patients’ investigations in order to make a
judgementofthepatients’suitabilitytoundergoapotentially
curative pelvic resection. Patient ﬁtness for major exenter-
ative surgery is of paramount concern for optimal results.
We and other centres have begun utilising cardiopulmonary
exercise (CPEX) testing in this regard [18].
Assessment of suitability for multivisceral resectional
surgery takes the form of a multimodality assessment in-
volving clinical evaluation (including digital rectal exami-
nation, examination under anaesthetic of the rectum and
vagina), endoscopic assessment, radiological assessment
(high-resolution MRI/endorectal ultrasound for local assess-
ment and computed tomography (chest/abdo/pelvis)/PET
CT for assessment of distant disease) and pathological
assessment. The primary aim of this assessment is to select
out those cases in which a curative resection is not feasible
in order to avoid unnecessary open and close type surgical
interventions and avoid exposing the patient to the risk of
surgical morbidity and mortality in cases in which surgery
would be ultimately futile.
6. ClinicalAssessment
Clinical assessment allows the experienced clinician to
correlate the ﬁndings of other investigative modalities with
their clinical ﬁndings and allows a better understanding of
the tumours relationship with the structures surrounding it.
It allows for a subjective assessment of ﬁxation which only
clinical examination is able to achieve as other investigations
are only able to suggest the possibility of tumour ﬁxation.
Fixation in itself is suggestive that a lesion may be less
likely to be amenable to curative resection but cannot on its
own contraindicate the possibility of surgical intervention.
Clinical assessment of ﬁxation can be graded in accordance
with the criteria established by Nicholls et al. in that
the tumour is either clinically mobile, tethered, or ﬁxed
[19]. In addition clinical examination gives the clinician an
assessment of the position of the tumour to aide in clinical
decision making and gives an assessment of the height of
theprimarytumourusefulinmakingdecisionsregardingthe
possibility of a restorative versus nonrestorative procedure.
7. Endoscopic Assessment
Endoscopic assessment is useful in the assessment of
tumours which may be out of the physical reach of a
clinically educated ﬁnger and allows assessment of the sizeInternational Journal of Surgical Oncology 3
of tumour, the degree of luminal obstruction (which may
be important if preoperative neoadjuvant therapy is required
as a defunctioning stoma may be required prior to therapy
commencement) and allows further pathological sampling
if required. Biopsy is essential to exclude squamous cell
carcinoma in anal canal lesions. In recurrent rectal cancer
biopsy is not always necessary if there is enough supportive
evidence such as a rising carcinoembryonic antigen (CEA)
level or a positive PET-CT scan.
8.LocalStaging
Local staging is conducted via means of a high-deﬁnition
Magnetic Resonance Imaging (MRI) scan using a rectal
cancer protocol. This is now well established as the standard
of care as the local staging investigation of choice in rectal
cancer [2, 20]. MRI is able to demonstrate the extent of local
invasion into surrounding anatomical structures to a high
degree of sensitivity and speciﬁcity. In addition, it is able to
help predict nodal status of the tumour, assess potential for
operability, exclude disease which is beyond operative sal-
vage, and help surgical teams plan their operative approach
[13]. As such it should be considered essential for assessment
of locally advanced tumours both at initial staging and
at subsequent restaging following neoadjuvant treatment
prior to surgical intervention. High-deﬁnition MRI has been
shown to have a high sensitivity in assessing the involvement
of the CRM and in suggesting the involvement of adjacent
organs [20, 21]. In a study of MRI involving assessment
of locally advanced tumours 22 of the cohorts 28 locally
advanced tumours were correctly diagnosed in advance
by the use of high-deﬁnition MRI scanning. Accuracy of
MRI does diminish for the lower-third rectal cancers where
endorectal ultrasound (ERUS) may be superior.
In assessment of pelvic tumours for pelvic exenterative
surgery, Popovich et al. [22] demonstrate an accuracy for
MRI of 83%, a PPV (positive predictive value) of 56%, and
an NPV (negative predictive value) of 100%. Our own data
(unpublished) found that the sensitivity of MRI in this set-
ting was 100% with a speciﬁcity of 66%. In the assessment of
T staging following chemoradiotherapy, sensitivity was just
84% and speciﬁcity 63%. We are presently basing our resec-
tion strategy on the ﬁndings of the imaging and assessment
at presentation rather than after neoadjuvant treatment.
Endorectal ultrasound (ERUS) has been demonstrated
to accurately categorize the depth of invasion of low rectal
tumours and accurately predict the involvement of adjacent
structures with accuracy for T stage as high as 96% [23].
However, this does not hold true for the use of ERUS
following treatment with accuracy falling as low as 50% in
one study of ERUS following chemoradiotherapy in locally
advanced disease [24].
9.DistantStaging
All patients being considered for pelvic clearance are staged
with computed tomography (CT) of the chest, abdomen
and pelvis to clarify local anatomy and exclude disseminated
malignancy. The presence of localised metastatic disease in
the liver or lung which is assessed as resectable according
to current guidelines can still be considered for pelvic
exenterative surgery.
Disease recurrence following exenterative surgery may
result from progressive disease in occult metastases [12, 25].
As such functional imaging using fused 18FDG positron
emission tomography CT (PET-CT) is recommended where
available, in order to minimise the risk of inappropriate
radical surgery on patients with distant disease which is
not amenable to surgical cure [12]. This has a sensitivity of
94.6% for colorectal liver metastases [26]. In addition due
to diﬃculties with MRI and ERUS in the reassessment of
tumours treated by neoadjuvant chemoradiotherapy PET-
CT may be more accurate in the local staging of tumours
following neoadjuvant therapy [27, 28] with the potential to
distinguish ﬁbrosis from residual tumour.
10. Classiﬁcation of Exenterations
Whilstitwouldbeadvantageoustohaveagreeddeﬁnitionsof
the types of exenterative surgery, this has not been possible
in practice making the literature diﬃcult to interpret. The
precisepelviccompartmentthatthetumourislocatedwithin
has a bearing on the likelihood of a complete (R0) resection
and the pattern of organs requiring removal. For example, it
is more challenging to obtain an R0 resection where there
is sidewall involvement [29]. Most classiﬁcation systems
proposed relate to recurrent rectal cancer, but the principles
translate to primary rectal cancer (Table 1). In the author’s
institution pelvic exenterations are classiﬁed into one of 5
main groups [11]: anterior pelvic exenterations (APE) which
in addition to the resection of central pelvic organs includes
removalofthebladderanddistaluretersbilaterally;posterior
pelvic exenteration (PPE) which involves removal of the cen-
tral organs together with the rectosigmoid (with or without
anal canal); total pelvic exenteration (TPE), a combination
of both anterior and posterior pelvic exenterations; extended
exenteration,whichincludesabdominosacralresection;indi-
vidualised approaches such as rectal excision with concomi-
tant radical prostatectomy with preservation of the bladder.
11. Contraindications to Surgery
Not all patients with locally advanced or recurrent rectal
cancer will be amenable to resection. Optimal outcomes
result from those patients in whom clear resection margins
are achieved so local staging is of paramount importance
in case selection. Clearly those patients with prohibitive co-
morbidities (ASA grade IV/V) will not be suitable for this
arduoussurgery,norwillthosewithadvancedmetastaticdis-
ease. Debulking surgery is not appropriate for patients with
rectal cancer so those with extensive disease are excluded.
Widely accepted local factors which contraindicate exen-
terative surgery include extension through the greater sciatic
notch, encasement of external iliac vessels, para-aortic
lymphadenopathy,andlowerlimboedemaindicatingvenous
or lymphatic obstruction [30].4 International Journal of Surgical Oncology
Table 1: Classiﬁcation of anatomical location of pelvic tumour.
Moore et al. [29]
Axial (perineal location; anastomotic
recurrence)
Anterior (urological/gynaecological
organ involvement)
Posterior (sacrum/coccyx involvement)
Lateral (pelvic sidewalls)
Yamada et al. [39]
Localized (adjacent pelvic organs or
connective tissue)
Sacral (S3–5, coccyx, or periosteum)
Lateral (lateral pelvic wall, S1 or 2,
sciatic nerve, or greater sciatic foramen)
RoyalMarsden
Central
Posterior/sacral
Lateral
Inferior/perineal
Anterior
supraperitoneal
at peritoneum
infraperitoneal
Whilst extensive sidewall involvement is generally con-
sidered to exclude patients for curative surgery, Solomon’s
unit has achieved long-term survival with no operative
mortality in 36 patients treated by en bloc lateral pelvic wall
dissection with internal and external iliac vascular resection
[31].
In terms of sacral excision with invasion present above
the S2-S3 junction, although this may be technically possible
to resect with some centres reporting successful outcomes in
small series [32], most units consider invasion above S2-S3
junction a relative contraindication to resection [30] as the
morbidity of surgery outweighs the beneﬁts.
12. NeoadjuvantandAdjuvantTherapy
Thejudicioususeofradiotherapycombinedwithextrafascial
rectal resection has been shown to optimise outcomes in
rectal cancer. Preoperative radiotherapy reduces local recur-
rence rates [32, 33] and is considered to be more eﬀective
than postoperative irradiation [34, 35]. In the context of
locally advanced rectal cancer, the decision to give preoper-
ative radiotherapy should be based on two considerations,
namely, whether the surgical resection margin is threatened
a n dc a nt h el o c a lr e c u r r e n c er a t eb er e d u c e d .I fc i r c u m f e r e n -
tial margin involvement is predicted by pre-operative assess-
ment to be absent and if involved organs can be resected en
bloc, then radiotherapy may not always be necessary.
When indicated, the author’s unit oﬀers combination
therapy as external beam radiotherapy of 45Gy in 25 frac-
tionsover5weekscombinedwith5-FU-basedchemotherapy
concomitantly (either infusional 5-FU or oral capecitabine).
Following neoadjuvant therapy formal restaging should
be performed routinely to reassess the resectability of the
tumour. This should again be undertaken with CT, MRI,
ERUS, EUA, and CT-PET as deemed appropriate by the
pelvic oncology MDT.
Adjuvant therapy is indicated for involved circumfer-
ential resection margins, nodal involvement, and extramu-
ral lymphovascular invasion. Intensive follow-up should
be maintained postoperatively, with clinical assessments
augmented with plasma CEA estimations at 6 monthly
intervals for the ﬁrst 2 years and annually thereafter [12,
36]. Computed tomography follow-up scanning of the chest
abdomen and pelvis should be conducted immediately
following completion of adjuvant therapy and annually
thereafter. Additional scanning or investigations may be
undertaken during follow-up as patients symptoms dictate.
13.Team Approach
The development of the pelvic oncology group in Swansea
has resulted in the accumulation of a large team of dedicated
practitioners from various aspects of medical and surgical
practice. Only with team working and major co-ordination
of eﬀorts is the practice of multivisceral resection possible
for any pelvic oncologic reason including locally advanced
rectal cancers. The team approach includes coordination
of multiple surgical teams often from diﬀerent hospitals to
attend a single patient’s operative journey at the right time
and in the right place with the right resources. There is fur-
ther team working required from professionals outside the
surgical ﬁeld and includes anaesthetists, intensivists, physi-
cian/gastroenterologists, haematology/blood bank, physio-
therapy, stoma therapists, continence advisors, and admin-
istrative support.
14. Surgery
For the radical treatment of locally advanced rectal carci-
nomas, there are various operations which may be deemed
appropriate for each patients case based on the clinical ﬁnd-
ings and the preoperative assessments. These include total
pelvic exenteration (TPE) for tumours of the rectum involv-
ing the bladder in the male or the hysterectomised female
patient, posterior pelvic exenteration (PPE) for female
patients in which the rectal tumour has invaded anteriorly
into the uterus, cervix, or proximal vagina, or a rectal exci-
sionwithenblocprostatectomyforlowrectaltumourssolely
invading the posterior aspect of the prostate without bladder
involvement; in these cases a radical prostatectomy is under-
taken with immediate bladder reconstitution. Rectal excision
may take the form of either an anterior resection if the rectal
tumour is high enough for safe and complete excision or as
an abdominoperineal excision of the rectum (APER). Lateral
pelvic lymph node dissection including obturator nodes is
performed in cases where cystoprostatectomy is undertaken.
The patient is usually positioned supine initially for both
TPEandPPEwithlegselevatedintheLloyd-Daviesposition.
A midline laparotomy is performed and a full inspection
of the abdominal viscera performed. Adhesions are dealtInternational Journal of Surgical Oncology 5
with as necessary. The sigmoid colon is mobilised initially
and the ureters identiﬁed bilaterally and traced towards the
pelvis. The sigmoid colon is then divided and the dissection
extended into the TME plane following which dissection is
tailored to each patient’s individual circumstances according
to the location of the primary tumour and the involved
organs. In principle all involved organs should be removed
en bloc without dividing the nonanatomical connections
between each organ. Following pelvic dissection perineal
dissection may be undertaken either in the supine Lloyd-
Davies position or in the prone jack-knife position if
sacrectomy is required. Low rectal anastomoses may be
feasible for high rectal tumours but are avoided if there is a
vesicourethral anastomosis following en bloc prostatectomy
to minimise ﬁstulation. The abdominal phase of an APER is
completed with the formation of a left-sided colostomy.
15.UrologicalandPlastic
ReconstructionApproaches
Urinary diversion is required in many cases, and this
is performed by constructing an ileal conduit following
ureteric anastomosis. Alternatively bladder augmentation
may be undertaken in cases in which a large volume of
bladder wall is resected without resection of the bladder in
its totality. Ureteric length is another important factor to
consider in reconstruction as continuity can require bladder
mobilisation and reimplantation, a bladder lengthening ﬂap
such as described by Casati and Boari [37] and Ockerblad
[38] , or even uretero-ureteral anastomosis with a common
channel to the bladder. As such a highly individualised
approach is required as dictated by local circumstances.
Plastic reconstruction aims to restore anatomy and
function and reduce complications. By importing well-
vascularised tissue into the exenterated pelvis, dead space
is minimised reducing the risk of haematoma formation
and sepsis. Pelvic ﬂoor reconstruction prevents perineal
herniation, while vaginal reconstruction can preserve sexual
function following en bloc vaginectomy. Importing healthy
tissue into an irradiated ﬁeld can reduce the frequency of
perineal wound complications.
Inclusion of a reconstructive plastic surgeon in the pelvic
oncology team gives the oncological surgeon freedom to
excise diseased tissues as widely as is necessary to gain
safe margins, without concern for how the defect will be
closed. Reconstruction is best performed as part of the
primary extirpative surgery, with the choice of technique
depending on factors including the intended procedure,
previous surgery, and comorbidities.
While most reconstructions can be planned pre-
operatively, unexpected intraoperative ﬁndings necessitate a
ﬂexible approach.
Reconstructive options include omentoplasty, porcine
dermal collagen implantation (Permacol, Covidien UK,
Gosport, Hampshire), local advancement or rotation ﬂaps,
and distant pedicled musculocutaneous ﬂaps. The pedi-
cled musculocutaneous ﬂaps commonly used include the
VRAM (vertical rectus abdominus musculocutaneous) ﬂap,
the IGAM (Inferior gluteal artery musculocutaneous), or
bilateral gracilis muscle ﬂaps.
16. Complications and Their Management
Complications following this extensive surgery are common,
and morbidity rates remain high in many series; the authors
own ﬁgures demonstrate a perioperative morbidity rate of
49% but a 30-day mortality rate of 0% [12]. Others have
demonstrated broadly similar morbidity rates of between
41% and 54% for overall morbidity rates and 0% to 7% for
30-day mortality rates [7, 12, 13, 40–42].
Complications of multivisceral resection include pelvic
collections/abscesses without evidence of anastomotic leaks,
anastomotic leaks, ﬁstulae of both bowel and urinary
tracts, necrotising fasciitis/cellulitis, pneumonia/atelectasis,
bleeding, prolonged ileus, early perineal hernias, wound
infection/breakdown, and ﬂap loss [7, 12, 13, 40–42]. These
early perioperative complications are managed according
to standard surgical principles, but institutional experience
will minimise and contain the sequalae when they occur.
Sepsis from whatever cause should be drained either per-
cutaneously or by further surgery and together with other
infectious complications treated initially by broad spectrum
antibiotics and subsequently by tailored antibiotic therapy
accordingtotheresultsofcultures.Anastomoticleaksshould
generally be dealt with surgically and commonly result in
loss of the anastomosis and exteriorisation of the bowel.
Fistulae can often be dealt with more conservatively with
drainage of sepsis followed by standard ﬁstula management
culminating in delayed surgical intervention should ﬁstula
output not settle. Wound breakdown and infection can often
be managed with antibiotics and topical negative pressure
therapy or regular wound dressings. Flap loss may be minor,
partial, or infrequently total. Often just the skin has to be
sacriﬁced in the case of musculocutaneous reconstruction.
17. Qualityof Life
It is striking how little attention has been made to quality of
life of patients undergoing this type of surgery with its high
attendant morbidity. Despite multivisceral pelvic resection
beingasigniﬁcantsurgicalinsultfrequentlyresultinginpost-
operative morbidity and temporary and permanent stomas,
there appears to be no evidence of a signiﬁcant deterioration
in quality of life in these patients when compared to those
with rectal carcinoma which is not locally advanced and
has been treated by anterior resection or abdominoperineal
resection [54, 57]. In a study of quality of life (QoL) in
patients who underwent pelvic exenteration for rectal cancer
[57], a comparison was made between patients undergoing
standard therapy for rectal cancer which was not locally
advanced (anterior resection/abdominoperineal resection)
compared to those with locally advanced disease who had
a “curative” pelvic exenteration. On two separate quality-
of- life scores (SF36 and FACT-C), there were broadly
comparable QoL scores in both tools, with FACT-C scores of
107.3versus106.4inthepelvicexenterationandlowanterior
resection/APE groups, respectively.6 International Journal of Surgical Oncology
18. Outcome Measures
Early reports of outcomes following pelvic exenteration
demonstrated poor quality of life together with signiﬁcant
levels of morbidity and mortality following surgery [4];
however, more recently there have been substantial improve-
ments in outcome following this type of surgery [42, 48, 50,
58–60]. In a 2007 study by a group in Rotterdam [61], the
authors published their 10-year outcomes for TPE. Over the
study period a total of 23 patients underwent TPE for locally
advanced primary rectal carcinoma, 19 patients (82.6%) had
a negative CRM following surgery, major morbidity was seen
in 6 patients (26.1%), and overall complication rate was
60.9%. Local control was 88% at 5 years, and overall 5-
year survival was 52%. Univariate analysis predicted adverse
outcomesforbothsurvivalandlocalrecurrencewithpositive
resection margins and the presence of preoperative pain.
The authors have previously published their results of
exenterative surgery from all forms of pelvic oncology [11]
which demonstrated that over the initial eleven years (1992–
2003) of the Swansea Pelvic Oncology group 130 patients
were assessed of which 76 underwent surgery with an intent
to cure. Of these 21 were converted to a palliative procedure
intraoperatively due to irresectable disease (27.6%). Failure
to undertake a curative resection was usually due to sacral
or vascular adherence by tumour invasion. Clear potentially
curative resection margins were achieved in 40 of the 55
(72.7%) patients who underwent surgery with a curative
intent. Thirty- day mortality for the 76 operative cases was
zero, reoperation rate for early complications was 3.9% (3
cases—bleeding, leak, and dehiscence).Ten patients required
readmission for late complications including stoma prob-
lems, small bowel obstruction, wound or pelvic abscesses,
and ﬁstulation. Overall morbidity in this mixed group was
28%. Follow-up of all 130 patients assessed for potential
multivisceral resection ranged from 1 to 120 months, with
a median survival in patients not undergoing surgery of
12 months, and there was not statistically signiﬁcant diﬀer-
ence in survival between patients not undergoing surgery
and those undergoing surgery with palliative intent and
those having surgery with a positive resection margin on
histological assessment. Survival in the patients with clear
histological margins was signiﬁcantly improved at 53% at 5
years.
More recently, the authors have published their results
with regards to multivisceral resection of locally advanced
primaryrectalcarcinoma[12].Thisstudyreportsthegroups’
results from multivisceral resection for purely T4 primary
rectal carcinoma. Between 2000 and 2009 a total of 42 locally
advanced primary rectal carcinomas underwent surgical
treatment with intent to cure. Thirty- one patients were male
and 11 female, age range from 41 to 83 (median 62). Twelve
were upper rectal cancers, 19 midrectal, and 11 low rectal.
Follow-up ranged from 2 to 102 months (median 30). Of
these 31 underwent neoadjuvant therapy with the remainder
not receiving pre-operative chemoradiotherapy treatment
due to tumour position (10 upper rectal carcinomas) and
1 having received previous prostatic radiotherapy. Fifty-ﬁve
percent had a local response to therapy. Of the surgical
procedures there were 23 cystoprostatectomies, 7 en bloc
bladder sparing radical prostatectomies, 10 radical hysterec-
tomies, and 1 sacrectomy. Pelvic reconstruction in this group
included7bilateralgracilismuscleﬂaps,29omentoplasties,2
porcinecollagenimplants,and3pedicledmusculocutaneous
ﬂaps (2 VRAM, 1 anterolateral thigh/vastus lateralis). An
R0 resection being achieved in 93% with nodal disease
was found in 69% and extramural vascular invasion in
33%. Thirty- day hospital mortality was zero, and overall
morbidity was 49%, 21% developing pelvic collection or
abscess, 10% anastomotic leak, 5% small bowel obstruction,
and 2% for each of vesicoperineal ﬁstula, spinal cord
ischaemia, rectovaginal ﬁstula, and incisional hernia. A total
of 8 patients (19%) had reoperation for complications.
Local recurrence rate in this series was 7% after a median
disease-free interval of 19 months. Five-year overall survival
inpatientswithcompleteresectionwas48%whichcompares
to 33% for those with residual local disease and zero at
3 years for those with metastatic disease. In this study
adverse outcome was associated on univariate analysis with
metastaticdisease,nodalmetastases,andextramuralvascular
invasion and the development of local recurrence.
There are many other studies which report the outcome
of exenterative surgery from around the world; a number
of these are shown in Table 2. As can be seen morbidity
is substantial in most series and varies between 27% and
83%; however, 30-day in-hospital mortality is generally low
(0%–9%), which is a signiﬁcant improvement on earlier
published results. This is despite an increasingly elderly
population with more frequent comorbidities, which is a
reﬂection of the improvements in peri- and postoperative
care facilities. Five-year survival varies between 20% and
83% being higher in the recurrent tumour series and in
series requiring sacrectomy. Local recurrence varies between
7 and 85%. Features which have been associated in these
studies with an adverse outcome include the presence of
metastases at surgery, node-positive disease, extramural
vascularinvasion,positivecircumferentialresectionmargins,
and poor diﬀerentiation amongst others. Consistency in
analysis of prognostic factors predicting adverse outcome is
poor, probably due to diﬀerences in factors analysed in each
study and the low numbers of cases analysed in many of the
published series.
19. Conclusions
Exenterativesurgeryforlocallyadvancedandrecurrentrectal
cancers is an established technique for the small number
of patients in each cancer network per year. Management
needs to be tailored to the individual patient drawing
on the experience of the multi-speciality pelvic oncology
team. The role of preoperative planning and careful case
selection cannot be underestimated. Oncological outcomes
are maximised in cases in which clear resection margins are
achieved and in the absence of markers of systemic disease
such as node positive disease or extramural lymphovascular
invasion. The authors consider that optimal outcomes can
onlybeachievedincentreswithinstitutionalexpertiseinthis
challenging yet rewarding patient group.International Journal of Surgical Oncology 7
Table 2: Outcomes in pelvic exenteration surgery.
Study N Tumour type Procedure type Morbidity Mortality 5-year survival LR rate Adverse prognostic
features
Austin and Solomon
[31] 36 All pelvic All 70% 0% 69% 28% n/a
Bakx et al. [43] 40 Rec. rectal All 83% 6% 28% n/a
Positive CRM,
symptomatic recurrence
at surgery, peripheral
recurrence
Bannura et al. [44]3 01 ◦ rectal PPE 50% 0% 48% 30% n/a
Derici et al. [40]5 7 1 ◦ rectal All 32% 3.5% 49% 18% Positive CRM, node
positive
Eckhauser et al. [45]1 2 1 ◦ rectal PPE, TPE 75% 8% 50% 36% n/a
Ferenschild et al. [46] 69 All pelvic TPE 67% 0% 38% 30% Positive CRM
Ferenschild et al. [47]2 5 1◦ and rec.
rectal
All and
sacrectomy 68% 0% 30% 66% Node positive, positive
CRM
Gannon et al. [7]4 5 1◦ and rec.
rectal PPE, TPE 47% 0% 52% 22% n/a
Harris et al. [12]4 2 1 ◦ rectal PPE, TPE 49% 0% 48% 7% Metastases, node
positive, EMVI
Ike et al. [48]7 1 1 ◦ rectal TPE 66% 4% 54% 28% Age, tumour stage, node
positive,
Ishiguro et al. [49]9 11 ◦ rectal PPE,TPE 41% 2% 52% 54%
Lateral pelvic LN
positivity, raised CEA,
EMVI
Larsen et al. [41] 124 1◦ rectal PPE, TPE 41% 2.5% 52% 15%
Age, annular tumour,
poor diﬀerentiation,
pelvis side wall resection,
transfusion
Law et al. [50]2 4 1◦ and rec.
rectal All 54% 0% 44% n/a n/a
Maetani et al. [51] 61 Rec. rectal All n/a 3% 28% 41% n/a
Melton et al. [52] 29 Rec. rectal TPE and
sacrectomy 59% 3.5% 20% 85%
Transfusion, positive
CRM, bone invasion,
anterior organ invasion
Moriya et al. [53] 128 1◦ rectal All 27% 1% 57% 34% BMI, node positive,
inﬂammatory reaction
Nguyen et al. [11] 76 All pelvic All 28% 0% 53% n/a n/a
Roos et al. [54]3 5 1◦ and rec.
rectal All 69% 3% 52% 12% Positive CRM,
preoperative pain
Verschueren et al.
[55] 11 1◦ rectal PPE, TPE 27% 9% 68% 9% n/a
Wiig et al. [56]6 1 ◦ rectal LAR/APR and
prostatectomy 66% 0% 83% n/a n/a
P˚ ahlman et al. [33] 28 All pelvic All 54% 7% n/a n/a n/a
Yamada et al. [5]6 4 1◦ and rec.
rectal
TPE, PPE, and
sacrectomy 56% 2% 39% n/a n/a
A P E :a n t e r i o rp e l v i ce x e n t e r a t i o n ,P P E :p o s t e r i o rp e l v i ce x e n t e r a t i o n ,T P E :t o t a lp e l v i ce x e n t e r a t i o n ,A l l :A P E ,P P E ,T P E ,L A R :l o wa n t e r i o rr e s e c tion, APR:
abdominoperineal.8 International Journal of Surgical Oncology
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